• Stock Information
  • FAQ’s
AIkido Pharma Inc.
  • About Us
  • Our Portfolio
    • Portfolio
    • AML & ALL
    • Antiviral Platform
    • Prostate Cancer
    • Pancreatic Cancer
  • Scientific Advisory Board
  • Published Papers
  • Investors
  • Contact Us
Select Page

KPC-34

Kucera Paper A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms

Kucera Paper Lipid Nucleoside Conjugates for the Treatment of Cancer

Kucers & Pardee Paper Improving Nucleoside Analogs via Lipid Conjugation

Short Summary of KPC34

The Phospholipid Gemcitabine Conjugate, KPC34, is a Novel Treatment for Leukemia

Wake Forest School of Medicine Study Phospholipiddeoxycytidine analogue prodrugs for the treatment of cancer

DHA-dFdC

Short-term Toxicity Study of DHA-dFdC

Study of DHA-dFdC

Synthesis and Cytotoxic Activity of Two Novel 1-Dodecylthio-2-decyloxypropyl-3-phosphatidic Acid Conjugates with Gemcitabine and Cytosine Arabinoside

GET

Email Alerts.

Receive the latest news & events.
GO

Company
Information.

AIkido Pharma Inc.

One Rockefeller Plaza
11th Floor
New York, NY 10020
info@aikidopharma.com

(212) 745-1374
  • Linkedin
  • Twitter
  • Home
  • About AIkido Pharma Inc.
  • Our Porfolio
  • Scientific Advisory Board
  • Contact Us
  • Latest News
  • Management Team
  • Board of Directors
  • Stock Information
  • Events
  • SEC Filings
  • FAQ’s
©2020 AIkido Pharma Inc. | All Rights Reserved.
Terms & Conditions | Privacy Policy